Keith Katkin, President and CEO at AVANIR PHARMACEUTICALS, INC. (AVNR), sold 4,385 shares at $4.14 ($18K) on 2013-11-01, disclosed to the SEC on 2013-11-05.
Scheduled sale ($18k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SNDX | BUY | 2025-05-19 | $91K | — | Filing → |
| SNDX | SELL | 2022-10-07 | $1.5M | — | Filing → |
| SNDX | SELL | 2022-10-04 | $176K | — | Filing → |